Trinity Biotech plc (TRIB)
| Market Cap | 7.83M -39.7% |
| Revenue (ttm) | 43.79M -28.9% |
| Net Income | -37.38M |
| EPS | -2.01 |
| Shares Out | 20.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 386,201 |
| Open | 0.3850 |
| Previous Close | 0.3913 |
| Day's Range | 0.3656 - 0.3947 |
| 52-Week Range | 0.3125 - 3.4400 |
| Beta | 1.00 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 16, 2026 |
About TRIB
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varice... [Read more]
Financial Performance
In 2025, Trinity Biotech's revenue was $43.79 million, a decrease of -28.87% compared to the previous year's $61.56 million. Losses were -$37.38 million, 17.6% more than in 2024.
Financial StatementsNews
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech's CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows ...
Trinity Biotech's Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling
- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by 2033 1...
Trinity Biotech terminates standby equity purchase agreement with Yorkville
Trinity Biotech (TRIB) announced that it has formally provided notice of termination to YA II PN, an affiliate of financing partner Yorkville Advisors Global, in respect of its standby equity…
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressi...
Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market
- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-p...
Trinity Biotech Earnings release: Q1 2026
Trinity Biotech released its Q1 2026 earnings on June 18, 2026, summarizing the period's financial results.
Trinity Biotech receives purchase orders for 2M units of TrinScreen HIV
Trinity Biotech (TRIB) announced that it has received additional purchase orders for over 2M units of its rapid HIV test, TrinScreen HIV. These orders are scheduled for fulfillment in Q3…
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on June 3, 2026, providing details about a securities offering with the SEC.
Trinity Biotech files to sell 167.95M American depositary shares
The 167.95M American depositary shares represent 3.36M ordinary shares.
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on May 13, 2026, providing details about a securities offering with the SEC.
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on May 13, 2026, providing details about a securities offering with the SEC.
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transfo...
Trinity Biotech Annual report: Q4 2025
Trinity Biotech has published its Q4 2025 annual report on April 30, 2026.
Trinity Biotech Slides: Q4 2025
Trinity Biotech has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on April 30, 2026.
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a global diagnostics company, today announced successful results from a clinical study of a new, enhanced ve...
Trinity Biotech announes collaboration agreement with University at Buffalo
Trinity Biotech (TRIB) announced it has entered into a collaboration agreement with the University at Buffalo, New York, or UB. The partnership focuses on advancing and commercializing a suite of…
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome
DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, inc...
Trinity Biotech begins rollout of glucose monitoring system in Brazil
Trinity Biotech (TRIB) has commenced the commercial rollout in Brazil of its updated laboratory blood glucose monitoring solution, the next-generation HbA1c column system for its Premier Hb9210 platfo...
Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech pl...
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
DUBLIN and WILSONVILLE, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solut...
Trinity Biotech announces advancements in CGM system development
John Gillard, CEO, commented: “These are some of the most important technical advancements to date in our CGM+ development program. The glucose measurement accuracy gains achieved by the incorporation...
Trinity Biotech says continuing to focus on Comprehensive Transformation Plan
The company said, “The Company’s key strategic objectives are to grow the existing business profitably and to advance its exciting innovation agenda, including the flagship development CGM+. As such, ...
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
- Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics ar...
Trinity Biotech sees Q4 revenue $11.5M-$12.5M vs. $15.9M last year
The company said, “The reduction in revenue between Quarter 4, 2024 and Quarter 4, 2025 was primarily driven by:The residual impact of the disruption to the global health market for…